|
|
NEUROENDOCRINOLOGY
LETTERS
including
Psychoneuroimmunology, Neuropsychopharmacology,
Reproductive Medicine, Chronobiology
and Human Ethology, ISSN 0172–780X
|
|
|
NEL
Vol.24 No.1/2, Feb-Apr 2003
ORIGINAL ARTICLE
Methoxytryptamine
effect on cisplatin-induced anemia
|
2003;
24:83–85
pii: NEL241203A13
PMID: 12743539
[Read
pdf 121kb]
Buy
PDF article
Check
Out
|
Reduction
of cisplatin-induced anemia by the pineal indole 5-methoxytryptamine
in metastatic lung cancer patients
Paolo
Lissoni, Fabio Malugani, Roberta Bukovec,
Veronica Bordin, Maristella Perego, Susan Mengo,
Antonio Ardizzoia & Gabriele Tancini
1.
Department of Internal Medicine, Regional General Hospital
“Casa Sollievo della Sofferenza”, Cappuccini Av., 71013 S.Giovanni
Rotondo (FG), ITALY.
2. Center of Chronobiology, Department of Internal Medicine,
University of Florence, Pieraccini Av., 50100 Florence (FI),
ITALY.
Submitted:
July 29, 2002 Accepted: August 7, 2002
Key
words:
chemotherapy-induced anemia, cisplatin, methoxytryptamine,
pineal indoles
|
Abstract
OBJECTIVE:
It has been demonstrated that the hematopoiesis is under a
neuroendocrine control, namely mediated by the pineal gland.
The pineal indole melatonin (MLT) has appeared to exert thrombopoietic
and lymphopoietic activity, whereas it has no relevant effect
on red cell differentiation. The present study was performed
to evaluate the influence of another pineal indole, the 5-methoxytryptamine
(5-MTT) on red cell line and hemoglobin production.
MATERIALS
& METHODS: The study was carried out in metastatic lung cancer
patients who underwent a chemotherapeutic combination containing
cisplatin, which is known to induce anemia. The study included
20 patients treated with cisplatin plus etoposide, who were
randomized to receive chemotherapy alone or chemotherapy plus
5-MTT (1 mg/day orally at noon every day).
RESULTS:
Hemoglobin mean blood concentrations significantly decreased
in both groups of patients. However, the decrease in hemoglobin
levels observed in patients treated with chemotherapy alone
was significantly higher with respect to that observed in
patients concomitantly treated with 5-MTT. Moreover, the percent
of patients who had no progressive disease on treatment was
significantly higher in the group treated with chemotherapy
plus 5-MTT.
CONCLUSIONS:
Even though the low number of patients does not allow us to
draw define conclusions, these preliminary results would show
that the concomitant administration of 5-MTT may reduce cisplatin-induced
anemia in cancer patients, by suggesting a hematopoietic activity
of 5-MTT on red cell line differentiation and hemoglobin production.
Moreover, the study would suggest that 5-MTT, as well as previously
demonstrated for MLT, may also enhance the cytotoxic activity
of cancer chemotherapy.
|
|
__________________________________________________________
Copyright © Neuroendocrinology Letters 2003
Society of Integrated Sciences
All rights reserved. No part may be reproduced, stored in a
retrieval system, or transmitted in any form or by any means,
electronic, mechanical, photocopying, recording, or ortherwise,
without prior written permission from the Editor-in-Chief.
The
latest statistics from the www.nel.edu
|
|
|
